BridgeBio Pharma Inc’s filing revealed that its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $0.61 million on Nov 19 ’24. In the deal valued at $22.41 per share,27,389 shares were sold. As a result of this transaction, Kumar Neil now holds 4,897,443 shares worth roughly $136.0 million.
Then, STEPHENSON BRIAN C sold 4,156 shares, generating $93,137 in total proceeds. Upon selling the shares at $22.41, the Secretary, Treasurer & CFO now owns 93,758 shares.
Before that, BRIAN STEPHENSON bought 4,156 shares. BridgeBio Pharma Inc shares valued at $92,887 were divested by the Officer at a price of $22.35 per share.
Scotiabank initiated its BridgeBio Pharma Inc [BBIO] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early October with a ‘”a Perform”‘ rating. Piper Sandler began covering BBIO with “an Overweight” recommendation on September 04, 2024.
Price Performance Review of BBIO
On Monday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 4.83% to $27.77. Over the last five days, the stock has gained 0.22%. BridgeBio Pharma Inc shares have fallen nearly -31.21% since the year began. Nevertheless, the stocks have fallen -28.41% over the past one year. While a 52-week high of $44.32 was reached on 02/15/24, a 52-week low of $21.62 was recorded on 06/24/24. SMA at 50 days reached $25.79, while 200 days put it at $26.61.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 26.95, which if violated will result in even more drops to 26.13. On the upside, there is a resistance level at 28.19. A further resistance level may holdings at 28.61. The Relative Strength Index (RSI) on the 14-day chart is 55.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.83, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 47.74%. Stochastics %K at 31.90% indicates the stock is a holding.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2024-11-29, dropping by -0.2 million shares to a total of 17.0 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 17.2 million shares. There was a decline of -1.18%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 31, 2024 when BMO Capital Markets began covering the stock and recommended ‘”a Market perform”‘ rating along with a $37 price target.
